AU2017330348B2 - Method to alleviate the symptoms of PMS - Google Patents

Method to alleviate the symptoms of PMS Download PDF

Info

Publication number
AU2017330348B2
AU2017330348B2 AU2017330348A AU2017330348A AU2017330348B2 AU 2017330348 B2 AU2017330348 B2 AU 2017330348B2 AU 2017330348 A AU2017330348 A AU 2017330348A AU 2017330348 A AU2017330348 A AU 2017330348A AU 2017330348 B2 AU2017330348 B2 AU 2017330348B2
Authority
AU
Australia
Prior art keywords
oxaloacetate
pms
individual
symptoms
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017330348A
Other languages
English (en)
Other versions
AU2017330348A1 (en
Inventor
Alan B. Cash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2017330348A1 publication Critical patent/AU2017330348A1/en
Application granted granted Critical
Publication of AU2017330348B2 publication Critical patent/AU2017330348B2/en
Priority to AU2023274237A priority Critical patent/AU2023274237B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017330348A 2016-09-22 2017-09-21 Method to alleviate the symptoms of PMS Active AU2017330348B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023274237A AU2023274237B2 (en) 2016-09-22 2023-12-04 Method to alleviate the symptoms of PMS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398319P 2016-09-22 2016-09-22
US62/398,319 2016-09-22
PCT/US2017/052718 WO2018057737A1 (en) 2016-09-22 2017-09-21 Method to alleviate the symptoms of pms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023274237A Division AU2023274237B2 (en) 2016-09-22 2023-12-04 Method to alleviate the symptoms of PMS

Publications (2)

Publication Number Publication Date
AU2017330348A1 AU2017330348A1 (en) 2019-04-11
AU2017330348B2 true AU2017330348B2 (en) 2023-09-07

Family

ID=59997500

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017330348A Active AU2017330348B2 (en) 2016-09-22 2017-09-21 Method to alleviate the symptoms of PMS
AU2023274237A Active AU2023274237B2 (en) 2016-09-22 2023-12-04 Method to alleviate the symptoms of PMS

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023274237A Active AU2023274237B2 (en) 2016-09-22 2023-12-04 Method to alleviate the symptoms of PMS

Country Status (8)

Country Link
US (4) US11071722B2 (OSRAM)
EP (1) EP3515428B1 (OSRAM)
JP (1) JP7291079B2 (OSRAM)
KR (1) KR102542842B1 (OSRAM)
AU (2) AU2017330348B2 (OSRAM)
CA (1) CA3037235A1 (OSRAM)
ES (1) ES2950096T3 (OSRAM)
WO (1) WO2018057737A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291079B2 (ja) 2016-09-22 2023-06-14 アラン ビー． キャッシュ， Ｐｍｓの症状を軽減する方法
PH12022551124A1 (en) 2020-01-01 2023-08-23 Celagenex Res India Pvt Ltd Synergistic nutritional compositions for enhancing atp efficiency
US20240075000A1 (en) * 2021-01-14 2024-03-07 Alan B. Cash Treatment of pathological fatigue with oxaloacetate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038701A1 (en) * 1996-04-12 1997-10-23 Neotech Medical Innovations In Composition and method for the treatment of premenstrual syndrome
EP3056199A1 (en) * 2015-02-12 2016-08-17 Alan B Cash Modification of the ph and other physical properties of oxaloacetic acid to allow for enhanced stability

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4670248A (en) * 1985-08-15 1987-06-02 International Minerals & Chemical Corp. Olivine bolus
US5155105A (en) 1986-09-15 1992-10-13 Bristol-Myers Squibb Company Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4839174A (en) 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
AT393221B (de) 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
SE462463B (sv) 1988-12-02 1990-07-02 Decken Alexandra V D Livs- och fodermedel innehaallande ketosyror
US4908213A (en) 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
CA2075517C (en) 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
US5474527A (en) 1993-03-29 1995-12-12 Bettinger; David S. Positive displacement transdermal system
AU6635994A (en) 1993-04-16 1994-11-08 Tufts University School Of Medicine Method for treatment of menopausal and premenstrual symptoms
FR2717389B1 (fr) 1994-03-18 1996-06-07 Lvmh Rech Utilisation du ginsénoside Ro ou d'un extrait végétal en contenant pour stimuler la synthèse du collagène.
US6057439A (en) 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US5612061A (en) 1994-10-14 1997-03-18 Rabkin; Simon W. Composition and method for the treatment of premenstrual syndrome
JP2874583B2 (ja) 1995-02-10 1999-03-24 日本電気株式会社 半導体装置の入力保護回路
US5569459A (en) 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
FR2730635B1 (fr) 1995-02-17 1997-05-09 Lvmh Rech Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de bertholletia
US5707630A (en) 1996-01-04 1998-01-13 Sabina International, Ltd. Herbal compound for relief of PMS through menopausal symptoms
US5654011A (en) 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements
US6987101B1 (en) 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
EP1019034A2 (en) 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
US6537969B1 (en) * 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
JP2001503447A (ja) 1998-04-27 2001-03-13 カラー アクセス，インコーポレイティド 老化皮膚の処置用組成物および方法
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
GB9820631D0 (en) 1998-09-22 1998-11-18 Unilever Plc Hair treatment composition, method and use
US7692067B2 (en) 2002-09-18 2010-04-06 Mendel Biotechnology, Inc. Yield and stress tolerance in transgenic plants
US6322823B1 (en) 1999-05-27 2001-11-27 Lenore C. Mannella PMS defense: an aromatherapy compound for the relief of symptoms of premenstrual syndrome
US6174542B1 (en) 1999-07-01 2001-01-16 Pms Mood Food, Inc. Dietary supplements and food products for treating symptoms of PMS
EP1274425A1 (en) 2000-04-18 2003-01-15 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor
US20020006910A1 (en) 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
US7473426B2 (en) 2001-02-27 2009-01-06 Yun Seok Choe Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract
US9783819B2 (en) 2001-03-27 2017-10-10 Mendel Biotechnology, Inc. Plant tolerance to low water, low nitrogen and cold II
NZ533242A (en) 2001-12-05 2007-11-30 Duramed Pharmaceuticals Inc Oral extended regime contraceptive package
US20030119913A1 (en) 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
DK1824470T3 (da) 2004-12-17 2014-08-18 Cash Alan Brian Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US8399432B2 (en) 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
ES2370790B2 (es) 2010-05-25 2012-10-18 Universidade De Santiago De Compostela Uso de oxalacetato en el tratamiento de isquemia.
WO2011163319A2 (en) * 2010-06-22 2011-12-29 Cash Alan B Activation of amp-protein activated kinase by oxaloacetate compounds
US20150210964A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Consumer Product Compositions
UY40582A (es) 2016-08-17 2024-01-15 Monsanto Technology Llc MÉTODOS, COMPOSICIONES y PLANTAS MEDIANTE LA MANIPULACIÓN DEL METABOLISMO DE GIBERELINA PARA AUMENTAR EL RENDIMIENTO COSECHABLE
JP7291079B2 (ja) 2016-09-22 2023-06-14 アラン ビー． キャッシュ， Ｐｍｓの症状を軽減する方法
WO2018097733A2 (en) 2016-11-23 2018-05-31 Bohne Askøy As Prevention and/or treatment of chronic fatigue syndrome
WO2019012159A1 (en) 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
US11332432B2 (en) 2018-09-30 2022-05-17 University Of Kansas Bioenergetically active esters for health and disease
US20240075000A1 (en) 2021-01-14 2024-03-07 Alan B. Cash Treatment of pathological fatigue with oxaloacetate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038701A1 (en) * 1996-04-12 1997-10-23 Neotech Medical Innovations In Composition and method for the treatment of premenstrual syndrome
EP3056199A1 (en) * 2015-02-12 2016-08-17 Alan B Cash Modification of the ph and other physical properties of oxaloacetic acid to allow for enhanced stability

Also Published As

Publication number Publication date
US20250262177A1 (en) 2025-08-21
AU2017330348A1 (en) 2019-04-11
EP3515428A1 (en) 2019-07-31
US11071722B2 (en) 2021-07-27
US11865092B2 (en) 2024-01-09
JP7291079B2 (ja) 2023-06-14
AU2023274237B2 (en) 2025-08-28
US20210308083A1 (en) 2021-10-07
EP3515428B1 (en) 2023-06-07
US20240115529A1 (en) 2024-04-11
JP2019529559A (ja) 2019-10-17
EP3515428C0 (en) 2023-06-07
ES2950096T3 (es) 2023-10-05
WO2018057737A1 (en) 2018-03-29
KR20190084248A (ko) 2019-07-16
CA3037235A1 (en) 2018-03-29
BR112019005581A2 (pt) 2019-06-11
KR102542842B1 (ko) 2023-06-14
US12324794B2 (en) 2025-06-10
US20190321315A1 (en) 2019-10-24
AU2023274237A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
US12324794B2 (en) Method to alleviate the symptoms of PMS
US20080096872A1 (en) Composition for Treatment of Pain Specification
JP4411414B2 (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
CN106794210A (zh) 包含山竹提取物或α、γ倒捻子素作为有效成分的牙周病预防或改善用组合物
WO2000009121A1 (en) Anti-inflammatory analgesics
JP2021119208A (ja) 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤
KR102231129B1 (ko) 수면 장애 치료용 발레리안 뿌리 추출물 및 라벤더 오일의 조합물
WO2019130215A1 (en) Cannabis compositions for the treatment of inflammatory skin disorders
WO2011163319A2 (en) Activation of amp-protein activated kinase by oxaloacetate compounds
US9265743B2 (en) Agent for inducing the synthesis of heat-shock proteins in human and animal cells
WO2012090194A2 (en) Compositions and methods for treating a skin disorder
KR101781671B1 (ko) 피부 콜라겐 산생 촉진제
RU2689321C2 (ru) Композиции и способы ингибирования синтеза триглицеридов с помощью синергетической комбинации ботанических составов
US20210059288A1 (en) Compositions and methods for treating aging and/or improving human health
KR102644611B1 (ko) 탈모 또는 피부 염증 억제용 조성물
AU2025271400A1 (en) Method to alleviate the symptoms of PMS
KR101997336B1 (ko) 에틸바닐린을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물
BR112019005581B1 (pt) Usos de oxaloacetato, ácido oxaloacético ou sal de oxaloacetato no tratamento de alívio dos sintomas da síndrome pré-menstrual
TWI815349B (zh) 山竹果殼萃取物用於製備促進糖尿病傷口癒合的藥物的用途
JP2012017270A (ja) 生体内グリケーション抑制剤
WO2025071432A1 (ru) Фармацевтическое средство для лечения артрологических заболеваний
FR3108036A1 (fr) Composition pharmaceutique ou diététique contenant l’extrait aqueux de la lavande et utilisable comme antidiabétique
WO2018144841A1 (en) Topical voriconazole for the treatment of pain
KR20110118425A (ko) 에리오딕티올을 유효성분으로 포함하는 알레르기 질환 예방 및 치료용 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)